Idarubicin administered during pregnancy: Its effects on the fetus

Gynecologic and Obstetric Investigation

Volumn 58, Issue 4, 2004, Pages 186-188

  Matsuo, Koji ^a   Shimoya, Koichiro ^a   Ueda, Shuji ^a   Wada, Kazuko ^a   Koyama, Masayasu ^a   Murata, Yuji ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Fetus; Idarubicin; Leukemia; Pregnancy

Indexed keywords

CREATINE KINASE; DAUNORUBICIN; IDARUBICIN;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AMNION FLUID; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; CESAREAN SECTION; CHEMOTHERAPY; CREATINE KINASE BLOOD LEVEL; DELIVERY; DRUG SAFETY; FEMALE; FETUS HEART RATE; GESTATIONAL AGE; HEART FAILURE; HUMAN; LIVER DISEASE; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; REMISSION; SEPTIC SHOCK; THIRD TRIMESTER PREGNANCY;

ADULT; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CESAREAN SECTION; DRUG THERAPY, COMBINATION; FEMALE; FETUS; GESTATIONAL AGE; HEART RATE, FETAL; HUMANS; IDARUBICIN; LEUKEMIA, MYELOCYTIC, ACUTE; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; SHOCK, SEPTIC; TREATMENT OUTCOME;

EID: 8344270335     PISSN: 03787346     EISSN: None     Source Type: Journal    
DOI: 10.1159/000079814     Document Type: Article

References (10)

1. Tobias JS, Bloom HJ: Doxorubicin in pregnancy. Lancet 1980;i:776.
2. Griffiths M: Acute leukaemia during pregnancy. Lancet 1988;i:586.
3. Borchmann P, Hubel K, Schnell R, Engert A: Idarubicin: A brief overview on pharmacology and clinical use. Int J Clin Pharmacol Ther 1997;35:80-83.
4. Hollingshead LM, Faulds D: Idarubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 1991;42:690-719.
5. Reynoso EE, Huerta F: Acute leukemia and pregnancy - Fatal fetal outcome after exposure to idarubicin during the second trimester. Acta Oncol 1994;33:709-710.
6. Achtari C, Hohlfeld P: Cardiotoxic transplacental effect of idarubicin administered during the second trimester of pregnancy. Am J Obstet Gynecol 2000;183:511-512.
7. Siu BL, Alonzo MR, Vargo TA, Fenrich AL: Transient dilated cardiomyopathy in a newborn exposed to idarubicin and all-trans-retinoic acid (ATRA) early in the second trimester of pregnancy. Int J Gynecol Cancer 2002;12:399-402.
8. Breccia M, Cimino G, Alimena G, De Carolis S, Lo Coco F, Mandelli F: AIDA treatment for high-risk acute promyelocytic leukemia in a pregnant woman at 21 weeks of gestation. Haematologica 2002;87:ELT12.
9. Claahsen HL, Semmekrot BA, van Dongen PW, Mattijssen V: Successful fetal outcome after exposure to idarubicin and cytosine-arabinoside during the second trimester of pregnancy - A case report. Am J Perinatol 1998;15:295-297.
10. Creasy RK, Resnik R, Iams J, et al: Maternal-Fetal Medicine, ed 5. Philadelphia, Saunders, 2003.